CF START
Research type
Research Study
Full title
The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF.
IRAS ID
211995
Contact name
Kevin Southern
Contact email
Eudract number
2016-002578-11
Duration of Study in the UK
8 years, 11 months, 31 days
Research summary
CF START is a national UK trial that will determine the safest and most effective antibiotic strategy for infants diagnosed with cystic fibrosis (CF). 480 CF infants will be randomly allocated either flucloxacillin prophylaxis (the current UK standard of care) or antibiotics given in a more targeted manner. The primary outcome will be the age at first growth of Pseudomonas aeruginosa from a respiratory culture (an important safety measure for families). All outcomes will be recorded on a national CF Registry, including a number of secondary outcomes assessing effectiveness and safety. Finally at 40-48 months, a measure of respiratory function will be undertaken in a central laboratory, which will provide a clearer indication of the effectiveness of these two strategies.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
16/NW/0629
Date of REC Opinion
16 Sep 2016
REC opinion
Further Information Favourable Opinion